Titan Biotech: From ₹8 to ₹400 — The 50x Multibagger Story | Value Investing #Shorts

Mbcover Titan Biotech From E282b98 - Manish Goel Portfolio Management Service

📅 Published
March 16, 2026 (Monday)

Titan Biotech (BSE: 524717) turned ₹8 into ₹400 — a stunning 50x multibagger return! Learn the 3 key factors that drove this incredible growth through value investing.

Figure 1. 5-year trajectory — Audited FY20-FY25 (Titan-illustrative)

Key Highlights:

Consistent Revenue Growth — From ₹60 Cr to ₹300+ Cr
Expanding Profit Margins — Operational efficiency at its best
Strong Management — Clear vision and strategic execution

📈 Want to find the next multibagger? Visit manishgoelpms.com

Manish Goel | SEBI Registered Research Analyst: INH100004775

Disclaimer: This content is for educational purposes only. Stock markets are subject to risks. Past performance does not guarantee future returns.

Figure 2. FY25 decomposition — Where the ratio comes from

📢 Join Our Telegram Channel

Get daily value investing lessons, stock analysis & Titan Biotech updates — delivered straight to your phone!

✈️ Join @longtermequityy on Telegram

🔔 Free • No spam • Value investing insights daily

Manish Goel

Manish Goel is a Chartered Accountant, SEBI Registered Research Analyst, and founder of Manish Goel PMS. A full-time value investor since 2010, he has helped thousands of investors build long-term wealth through quality stock picking and disciplined fundamental analysis.

See Full Bio

Titan Biotech: From ₹8 to ₹400 — The 50x Multibagger Story | Value Investing #Shorts

Rupee at ₹93/$ — Why This Is a Golden Opportunity for Pharma & Biotech Investors

Titan Biotech 50x Deep Dive: Complete Value Investing Analysis — How ₹8 Became ₹400

Titan Biotech: From ₹8 to ₹400 — The 50x Multibagger Story | Value Investing #Shorts

Key Highlights:

Related posts

Titan Biotech 50x Deep Dive: Complete Value Investing Analysis — How ₹8 Became ₹400